Intralipid® 20% is metabolized and utilized as a source of energy and a contribution to the physical environment and to provide an additional moisture dependent upon entry of external air during administration.

The major component fatty acids are linoleic acid (44‑62%), oleic acid (16 %, 18%), palmitic acid (5%‑10%) and stearic acid (4%‑5%). R1COH, R2CH2COH and R3COH contain saturated and unsaturated fatty acids that absorb in neutral fats, is primarily either the cis or trans isomer of phytanic acid. In any case, the total caloric value, including fat, phospholipid and glycerol, is 20%.

For the Intralipid® 20% emulsion, the total caloric value is 10.5 kcal/mL. The fat content is 20% (419 kcal/mL). The total caloric value is 1.28 kcal/hour/mL. The ratio of fat to carbohydrate is 1:1:8.

INDICATIONS AND USAGE

Intralipid 20% is indicated as a source of essential and nonessential fatty acids for patients requiring parenteral nutrition for an extended period of time (more than 10 days). Intralipid 20% is not intended for use in patients who require fat-free diets.

CONTRAINDICATIONS

Intralipid 20% is contraindicated in patients with disturbances of normal fat metabolism such as fasting or dietary lipaemia, pancreatic or hepatobiliary disease or acromegaly. In patients with hypertriglyceridemia, the use of Intralipid 20% should be avoided.

WARNINGS

During intravenous fat infusion of Intralipid® 20%, patients should be monitored for evidence of hyperlipidemia. Hyperlipidemia findings include increased serum triglycerides and plasma free fatty acids, increased serum cholesterol and phospholipids, and small dense low density lipoprotein particles. Patients with hypertriglyceridemia should be monitored closely to avoid adverse effects such as those observed in case reports. The risk of hypertriglyceridemia and pancreatitis is increased in patients with hypertriglyceridemia. The risk of hypertriglyceridemia is increased in patients with acromegaly. Intralipid® 20% should be used cautiously in patients with diabetes mellitus. Intralipid® 20% should be used with caution in patients with hypercholesterolemia. Intralipid® 20% should be used with caution in patients with liver disease. Intralipid® 20% should be used with caution in patients with renal impairment. Intralipid® 20% should be used with caution in patients with impaired fat metabolism.

Intralipid® 20% is metabolized and utilized as a source of energy and a contribution to the physical environment and to provide an additional moisture dependent upon entry of external air during administration.

The major component fatty acids are linoleic acid (44‑62%), oleic acid (16 %, 18%), palmitic acid (5%‑10%) and stearic acid (4%‑5%). R1COH, R2CH2COH and R3COH contain saturated and unsaturated fatty acids that absorb in neutral fats, is primarily either the cis or trans isomer of phytanic acid. In any case, the total caloric value, including fat, phospholipid and glycerol, is 20%.

INDICATIONS AND USAGE

Intralipid® 20% is indicated as a source of essential and nonessential fatty acids for patients requiring parenteral nutrition for an extended period of time (more than 10 days). Intralipid® 20% is not intended for use in patients who require fat-free diets.

Contraindications

Intralipid® 20% is contraindicated in patients with disturbances of normal fat metabolism such as fasting or dietary lipaemia, pancreatic or hepatobiliary disease or acromegaly. In patients with hypertriglyceridemia, the use of Intralipid® 20% should be avoided.

Warnings

During intravenous fat infusion of Intralipid® 20%, patients should be monitored for evidence of hyperlipidemia. Hyperlipidemia findings include increased serum triglycerides and plasma free fatty acids, increased serum cholesterol and phospholipids, and small dense low density lipoprotein particles. Patients with hypertriglyceridemia should be monitored closely to avoid adverse effects such as those observed in case reports. The risk of hypertriglyceridemia and pancreatitis is increased in patients with hypertriglyceridemia. The risk of hypertriglyceridemia is increased in patients with acromegaly. Intralipid® 20% should be used cautiously in patients with diabetes mellitus. Intralipid® 20% should be used with caution in patients with hypercholesterolemia. Intralipid® 20% should be used with caution in patients with liver disease. Intralipid® 20% should be used with caution in patients with renal impairment. Intralipid® 20% should be used with caution in patients with impaired fat metabolism.

Intralipid® 20% is metabolized and utilized as a source of energy and a contribution to the physical environment and to provide an additional moisture dependent upon entry of external air during administration.

The major component fatty acids are linoleic acid (44‑62%), oleic acid (16 %, 18%), palmitic acid (5%‑10%) and stearic acid (4%‑5%). R1COH, R2CH2COH and R3COH contain saturated and unsaturated fatty acids that absorb in neutral fats, is primarily either the cis or trans isomer of phytanic acid. In any case, the total caloric value, including fat, phospholipid and glycerol, is 20%.

Indications and Usage

Intralipid® 20% is indicated as a source of essential and nonessential fatty acids for patients requiring parenteral nutrition for an extended period of time (more than 10 days). Intralipid® 20% is not intended for use in patients who require fat-free diets.

Contraindications

Intralipid® 20% is contraindicated in patients with disturbances of normal fat metabolism such as fasting or dietary lipaemia, pancreatic or hepatobiliary disease or acromegaly. In patients with hypertriglyceridemia, the use of Intralipid® 20% should be avoided.

Warnings

During intravenous fat infusion of Intralipid® 20%, patients should be monitored for evidence of hyperlipidemia. Hyperlipidemia findings include increased serum triglycerides and plasma free fatty acids, increased serum cholesterol and phospholipids, and small dense low density lipoprotein particles. Patients with hypertriglyceridemia should be monitored closely to avoid adverse effects such as those observed in case reports. The risk of hypertriglyceridemia and pancreatitis is increased in patients with hypertriglyceridemia. The risk of hypertriglyceridemia is increased in patients with acromegaly. Intralipid® 20% should be used cautiously in patients with diabetes mellitus. Intralipid® 20% should be used with caution in patients with hypercholesterolemia. Intralipid® 20% should be used with caution in patients with liver disease. Intralipid® 20% should be used with caution in patients with renal impairment. Intralipid® 20% should be used with caution in patients with impaired fat metabolism.
The prime destabilizers of emulsions are excessive acidity (low pH) and inappropriate electrolyte content. Careful consideration should be given to additions of divalent cations Ca++ and Mg++ which have been shown to cause emulsion instability. Amino acid solutions exert a buffering effect protecting the emulsion. The admixture should be inspected carefully for "breaking or oiling out" of the emulsion. "Breaking or oiling out" is described as the separation of the emulsion and can be visibly identified by a yellowish streaking or the accumulation of yellowish droplets in the admixed emulsion. The admixture must also be examined for particulates. The admixture must be discarded if any of the above is observed.

HOW SUPPLIED

Intralipid® 20% is supplied as a sterile emulsion in the following fill sizes: 100 mL, 250 mL and 500 mL.

- 100 mL: 0338‑0519‑58
- 250 mL: 0338‑0519‑09
- 500 mL: 0338 0519‑13

Intralipid® 20% is also available as Pharmacy Bulk Package in the following fill size.

- 1000 mL: 0338‑0519‑14

STORAGE

Intralipid® 20% should not be stored above 25°C (77°F). Do not freeze Intralipid® 20%. If accidentally frozen, discard the bag.

REFERENCES


(May 2015)

Manufactured for

Baxter Healthcare Corporation

Deerfield, IL 60015 USA

Manufactured by

Fresenius Kabi

Uppsala, Sweden

Intralipid® is a registered trademark of Fresenius Kabi AB.